Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jun 25;156(12):602-605.
doi: 10.1016/j.medcle.2021.01.004. Epub 2021 May 24.

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation

Ismael Francisco Aomar-Millán  1 , Juan Salvatierra  2 , Úrsula Torres-Parejo  3 , María Nuñez-Nuñez  4   5 , José Hernández-Quero  5 , Francisco Anguita-Santos  5
Affiliations
Case Reports

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation

Ismael Francisco Aomar-Millán et al. Med Clin (Engl Ed). .

Abstract
in English, Spanish

Aim: To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation.

Methods: A retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divided into three treatment groups (pulses of methylprednisolone alone [group I], tocilizumab alone [group II] and methylprednisolone plus tocilizumab [group III]). The aim was to assess intergroups differences in the clinical course with a 60-day follow-up and related analytical factors.

Results: 14 patients (9,8%) died: 8 (10%) in group I and 6 (9,5%) in groups II and III. 15 (10,6%) were admitted to ICU: 2 (2,5%) from group I, 4 (28,5%) from group II and 9 (18,4%) from group III. The mean hospital stay was longer in group II and clinical outcome was not associated with treatment.

Conclusions: Tocilizumab seems to be not associated with better clinical outcomes and should be reserved for clinical trial scenario, since its widespread use may result in higher rate of ICU admission and longer mean hospital stay without differences in mortality rate and potentially adverse events.

Objetivos: Analizar si existen diferencias en desenlaces clínicos según el tratamiento inmunosupresor recibido en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada.

Métodos: Estudio de cohortes retrospectivo de 142 pacientes con neumonía grave COVID-19 e inflamación moderada. Se dividieron en tres grupos de tratamiento (pulsos de metilprednisolona solo [grupo I], tocilizumab solo [grupo II] y metilprednisolona más tocilizumab [grupo III]). Analizamos las diferencias intergrupos en el curso clínico con un seguimiento de 60 días y factores clínicos analíticos relacionados.

Resultados: Fallecieron 14 pacientes (9,8%): 8 (10%) del grupo I y 6 (9,5%) de los grupos II y III. Quince (10,6%) ingresaron en UCI: 2 (2,5%) del grupo I, 4 (28,5%) del grupo II y 9 (18,4%) del grupo III. La estancia media hospitalaria fue mayor en los del grupo II. La evolución clínica no se asoció al tratamiento administrado.

Conclusiones: El uso de tocilizumab debería reservarse para escenarios de ensayos clínicos. Su utilización generalizada podría acompañarse de mayor estancia media hospitalaria e ingreso en UCI sin diferencias en la mortalidad con un potencial aumento de efectos adversos.

Keywords: COVID-19; Cytokine storm syndrome; Inflammation; Methylprednisolone; Tocilizumab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Days of mean hospital stay according to treatment received.
See this image and copyright information in PMC

References

    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
    1. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436. - DOI - PMC - PubMed
    1. Fadel R., Morrison A.R., Vahia A., Smith Z.R., Chaudhry Z., Bhargava P., et al. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020;71:2114–2120. doi: 10.1093/cid/ciaa601. - DOI - PMC - PubMed
    1. Ramiro S., Mostard R.L.M., Magro-Checa C., van Dongen C.M.P., Dormans T., Buijs J., et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020;79:1143–1151. doi: 10.1136/annrheumdis-2020-218479. - DOI - PMC - PubMed
    1. Guaraldi G., Marianna Meschiari M., Cozzi-Lepri A., Milic J., Tonelli R., Menozzi M., et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2:e474–e484. doi: 10.1016/S2665-9913(20)30173-9. - DOI - PMC - PubMed

Publication types

LinkOut - more resources